SIGNIFICANCE OF GENE AMPLIFICATIONS ON RELAPSE-FREE SURVIVAL (RFS) AND OVERALL SURVIVAL (OS) IN METASTATIC BREAST CANCER

被引：0
|
作者：
Todorovic-Rakovic, Natasa [1 ]
Neskovic-Konstantinovic, Zora [1 ]
Nikolic-Vukosavljevic, Dragica [1 ]
机构：
[1] Inst Oncol & Radiol Serbia, Belgrade, Serbia
来源：
BREAST | 2013年 / 22卷
关键词：
D O I：
10.1016/S0960-9776(13)70131-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S59 / S60
页数：2
相关论文
共 50 条
  • [41] Negative association between GATA3 and fascin could predict relapse-free and overall survival in patients with breast cancer
    Kyueng-Whan Min
    Dong-Hoon Kim
    Sung-Im Do
    Seoung Wan Chae
    Kyungeun Kim
    Jin Hee Sohn
    Jung-Soo Pyo
    Hyun Joo Lee
    Dong Hyun Kim
    Sukjoong Oh
    Seon Hyeong Choi
    Yong Lai Park
    Chan Heun Park
    Eun-Kyung Kim
    Mi Jung Kwon
    Jinwon Seo
    Kyoung Min Moon
    Virchows Archiv, 2016, 468 : 409 - 416
  • [42] Body mass index (BMI), tumor subtype, and relapse-free survival (RFS) in CALGB 9741 (Alliance)
    Ligibel, Jennifer A.
    Cirrincione, Constance
    Liu, Minetta C.
    Citron, Marc L.
    Ingle, James N.
    Gradishar, William John
    Martino, Silvana
    Sikov, William M.
    Michaelson, Richard Alan
    Hudis, Clifford
    Winer, Eric P.
    Barry, William Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [43] 4-year relapse-free survival (RFS), overall survival (OS) and long-term toxicity of (neo)adjuvant ipilimumab (IPI) plus nivolumab (NIVO) in macroscopic stage III melanoma: OpACIN trial
    Versluis, J. M.
    Reijers, I. L. M.
    Rozeman, E. A.
    Sikorska, K.
    van Houdt, W. J.
    van Thienen, J. V.
    Adriaansz, S. A.
    Mallo, H.
    van Tinteren, H.
    van de Wiel, B. A.
    Grijpink-Ongering, L. G.
    Bruining, A.
    Haanen, J. B. A. G.
    van Akkooi, A. C. J.
    Schumacher, T. N.
    Blank, C. U.
    ANNALS OF ONCOLOGY, 2020, 31 : S742 - S743
  • [44] 3-year relapse-free survival (RFS), overall survival (OS) and long-term toxicity of (neo)adjuvant ipilimumab (IPI) plus nivolumab (NIVO) in macroscopic stage III melanoma (OpACIN trial)
    Blank, C. U.
    Versluis, J. M.
    Reijers, I. L. M.
    Sikorska, K.
    van Houdt, W. J.
    van Thienen, J. V.
    Adriaansz, S.
    Mallo, H. A.
    van Tinteren, H.
    van de Wiel, B. A.
    Grijpink-Ongering, L. G.
    Bruining, A.
    Haanen, J. B. A. G.
    van Akkooi, A. C. J.
    Schumacher, T. N.
    Rozeman, E. A.
    ANNALS OF ONCOLOGY, 2019, 30 : 535 - 535
  • [45] A competing risks cure frailty model: An application to relapse-free survival of breast cancer patients
    Ghavami, Vahid
    Mahmoudi, Mahmood
    Foroushani, Abbas Rahimi
    Baghishani, Hossein
    Yaseri, Mehdi
    Shandiz, Fatemeh Homaei
    PAKISTAN JOURNAL OF STATISTICS AND OPERATION RESEARCH, 2021, 17 (03) : 591 - 605
  • [46] LGR5 overexpression confers poor relapse-free survival in breast cancer patients
    Hou, Ming-Feng
    Chen, Po-Ming
    Chu, Pei-Yi
    BMC CANCER, 2018, 18
  • [47] RELAPSE-FREE SURVIVAL IN BREAST-CANCER PATIENTS - THE IMPORTANCE OF THE PRESENCE OF PROGESTERONE RECEPTORS FOR PROGNOSIS
    ZIELINSKI, CC
    KUZMITS, R
    SPONA, J
    SALZER, H
    KUBISTA, E
    STAFFEN, A
    AIGINGER, P
    BLUT, 1984, 49 (03): : 243 - 243
  • [48] LGR5 overexpression confers poor relapse-free survival in breast cancer patients
    Ming-Feng Hou
    Po-Ming Chen
    Pei-Yi Chu
    BMC Cancer, 18
  • [49] Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy
    Suciu, Stefan
    Eggermont, Alexander M. M.
    Lorigan, Paul
    Kirkwood, John M.
    Markovic, Svetomir N.
    Garbe, Claus
    Cameron, David
    Kotapati, Srividya
    Chen, Tai-Tsang
    Wheatley, Keith
    Ives, Natalie
    de Schaetzen, Gaetan
    Efendi, Achmad
    Buyse, Marc
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (01): : 87 - 96
  • [50] Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial
    Dummer, R.
    Schadendorf, D.
    Hauschild, A.
    Santinami, M.
    Atkinson, V. G.
    Mandala, M.
    Sileni, V. Chiarion
    Larkin, J.
    Nyakas, M. S.
    Dutriaux, C.
    Haydon, A.
    Mortier, L.
    Robert, C.
    Schachter, J.
    Feng, X.
    de Jong, E.
    Mookerjee, B.
    Kefford, R.
    Kirkwood, J. M.
    Long, G. V.
    ANNALS OF ONCOLOGY, 2018, 29 : 445 - 445
12345